Enamel matrix derivative (EMD; Emdogain) vs placebo or control
Postoperative complications (infection) / adverse events · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…
1 finding from 1 review
- Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes1 year (time-points 1, 5 and 10 years planned)No particular adverse events or infection attributable to EMD in any trial; no differences in pain, edema, hematoma, wound dehiscence or root sensitivity (Tonetti 2002).9 studiesGRADE not reported